Rockville – Aeras and the Infectious Disease Research Institute (IDRI) have commenced first clinical trial of IDRI's novel tuberculosis vaccine candidate, ID93 GLA-SE, the global non-profit organisation Aeras announced Wednesday.
Hebei Xingang Pharmaceutical Co., Ltd.
Professional manufacturer of Rifampicin and Rifamycin Derivatives